2003 JAN 9 - (NewsRx.com & NewsRx.net) -- Results of a study of thalidomide for treatment of relapsed and refractory relapsed multiple myeloma suggest further assessment is warranted for treatment with the compound.
"Thalidomide (Thal) can overcome drug resistance in multiple myeloma (MM) but is associated with somnolence, constipation, and neuropathy," said P.G. Richardson and colleagues at Harvard University's School of Medicine.
They had shown, in vitro, "that the potent immunomodulatory derivative of thalidomide (IMID) CC-5013 induces apoptosis or growth arrest even in resistant MM cell lines and patient cells, decreases binding of MM cells to bone …
No comments:
Post a Comment